Prof. Rifaat Safadi and his team are developing an inhaled formulation that combines two FDA-approved drugs, which recruit and activate certain types of immune cells in patients with Acute Respiratory Distress Syndrome (ARDS).
The inhaled formulation will enable a safer use of the drugs locally in the lung.
The drugs are expected to exert a synergistic action.
Prof. Safadi's team is planning to clinically test the drugs separately and in the combined inhaled form in patients, for the benefit of COVID-19 patients.
1586128467.png)